[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100528941":3},{"organization":4,"outcomesModule":7,"designInfo":40,"detailedDescription":15,"studyPopulation":15,"armGroups":46,"interventions":74,"overallOfficials":88,"centralContacts":92,"locations":98,"responsibleParty":170,"collaborators":15,"id":172,"slug":15,"hasResults":173,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":15,"eligibilityCriteria":177,"healthyVolunteers":173,"sex":178,"minAge":179,"maxAge":15,"enrollmentInfo":180,"targetDuration":15,"studyType":183,"phases":184,"briefSummary":186,"conditions":187,"keywords":15,"overallStatus":101,"whyStopped":15,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":198},{"fullName":5,"class":6},"Gilead Sciences","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":18,"otherOutcomes":15},[9,13,16],{"measure":10,"description":11,"timeFrame":12},"The Number of Participants with Dose Limiting Toxicities (DLTs) During Dose Escalation","DLTs are defined as any of the following treatment-emergent adverse events (AEs) regardless of attribution (graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0), unless clearly related to an underlying disease or extraneous causes, with onset within the DLT-evaluation period for the corresponding dose.","First dose up to 30 days post last dose (Up to approximately 109 weeks).",{"measure":14,"description":15,"timeFrame":12},"The Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)",null,{"measure":17,"description":15,"timeFrame":12},"The Incidence of Laboratory Abnormalities",[19,23,26,29,32,34,36,38],{"measure":20,"description":21,"timeFrame":22},"Pharmacokinetic (PK) Parameter: Area Under the Concentration (AUC)0-24 of GS-0201","AUC0-24 is defined as the concentration of drug over time between time 0 and time 24 hours.","Predose and postdose up to end of treatment (up to 105 weeks)",{"measure":24,"description":25,"timeFrame":22},"PK Parameter: Cmax of GS-0201","Cmax is defined as the maximum observed drug concentration.",{"measure":27,"description":28,"timeFrame":22},"PK Parameter: Tmax of GS-0201","Tmax is defined as the time to maximum observed concentration.",{"measure":30,"description":31,"timeFrame":22},"PK Parameter: AUC0-168 of SG (Parts C and D only)","AUC0-168 is defined as the concentration of drug over time between time 0 and time 168 hours.",{"measure":33,"description":25,"timeFrame":22},"PK Parameter: Cmax of SG (Parts C and D only)",{"measure":35,"description":28,"timeFrame":22},"PK Parameter: Tmax of SG (Parts C and D only)",{"measure":37,"description":15,"timeFrame":22},"GS-0201 Plasma Concentrations",{"measure":39,"description":15,"timeFrame":22},"Sacituzumab Govitecan (SG) Serum Concentrations (Parts C and D only)",{"allocation":41,"interventionModel":42,"interventionModelDescription":15,"primaryPurpose":43,"observationalModel":15,"timePerspective":15,"maskingInfo":44},"NON_RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":45,"maskingDescription":15,"whoMasked":15},"NONE",[47,53,57,61,66,70],{"label":48,"type":49,"description":50,"interventionNames":51},"Part A: GS-0201 Monotherapy Dose Escalation","EXPERIMENTAL","Participants will receive escalating doses of GS-0201 monotherapy, until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol or up to 105 weeks, whichever occurs first.",[52],"Drug: GS-0201",{"label":54,"type":49,"description":55,"interventionNames":56},"Part B: Cohort B1: GS-0201 Monotherapy Dose Expansion","Participants with selected breast cancer indication will receive GS-0201 monotherapy at the recommended dose for expansion.",[52],{"label":58,"type":49,"description":59,"interventionNames":60},"Part B: Cohort B2: GS-0201 Monotherapy Dose Expansion","Participants with selected indications not included in cohort B1 will receive GS-0201 monotherapy at the recommended dose for expansion.",[52],{"label":62,"type":49,"description":63,"interventionNames":64},"Part C: Dose Escalation: GS-0201 + Sacituzumab Govitecan (SG)","Participants will receive escalating doses of GS-0201 in combination with SG, until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol or up to 105 weeks, whichever occurs first.",[52,65],"Drug: Sacituzumab Govitecan",{"label":67,"type":49,"description":68,"interventionNames":69},"Part D: Cohort D1: Dose Expansion: GS-0201 + SG","Participants with confirmed unresectable locally advanced or metastatic triple negative breast cancer (mTNBC) will receive GS-0201 at the recommended Phase 2 dose (RP2D) in combination with SG.",[52,65],{"label":71,"type":49,"description":72,"interventionNames":73},"Part D: Cohort D2: Dose Expansion: GS-0201 + SG","Participants with recurrent\u002Fpersistent endometrial cancer will receive GS-0201 at the recommended Phase 2 dose (RP2D) in combination with SG.",[52,65],[75,80],{"type":76,"name":77,"description":78,"armGroupLabels":79,"otherNames":15},"DRUG","GS-0201","Pill administered orally",[48,54,58,62,67,71],{"type":76,"name":81,"description":82,"armGroupLabels":83,"otherNames":84},"Sacituzumab Govitecan","Administered intravenously",[62,67,71],[85,86,87],"IMMU-132","Trodelvy™","GS-0132",[89],{"name":90,"affiliation":5,"role":91},"Gilead Study Director","STUDY_DIRECTOR",[93],{"name":94,"role":95,"phone":96,"phoneExt":15,"email":97},"Gilead Clinical Study Information Center","CONTACT","1-833-445-3230 (GILEAD-0)","GileadClinicalTrials@gilead.com",[99,113,123,132,141,152,161],{"facility":100,"status":101,"city":102,"state":103,"zip":104,"country":105,"countryCode":106,"cosmosGeoPoint":107,"geoPoint":112,"contacts":15},"Dana-Farber Cancer Institute","RECRUITING","Boston","Massachusetts","02459","United States","US",{"type":108,"coordinates":109},"Point",[110,111],-71.05977,42.35843,{"lat":111,"lon":110},{"facility":114,"status":101,"city":115,"state":116,"zip":117,"country":105,"countryCode":106,"cosmosGeoPoint":118,"geoPoint":122,"contacts":15},"NEXT Austin","Austin","Texas","78758",{"type":108,"coordinates":119},[120,121],-97.74306,30.26715,{"lat":121,"lon":120},{"facility":124,"status":101,"city":125,"state":116,"zip":126,"country":105,"countryCode":106,"cosmosGeoPoint":127,"geoPoint":131,"contacts":15},"The University of Texas MD Anderson Cancer Center","Houston","77030",{"type":108,"coordinates":128},[129,130],-95.36327,29.76328,{"lat":130,"lon":129},{"facility":133,"status":101,"city":134,"state":116,"zip":135,"country":105,"countryCode":106,"cosmosGeoPoint":136,"geoPoint":140,"contacts":15},"NEXT Dallas","Irving","75039",{"type":108,"coordinates":137},[138,139],-96.94889,32.81402,{"lat":139,"lon":138},{"facility":142,"status":101,"city":143,"state":15,"zip":144,"country":145,"countryCode":146,"cosmosGeoPoint":147,"geoPoint":151,"contacts":15},"Rambam Health Care Campus","Haifa","31096","Israel","IL",{"type":108,"coordinates":148},[149,150],34.99928,32.81303,{"lat":150,"lon":149},{"facility":153,"status":101,"city":154,"state":15,"zip":155,"country":145,"countryCode":146,"cosmosGeoPoint":156,"geoPoint":160,"contacts":15},"Tel Aviv Sourasky Medical Center","Tel Aviv","6423906",{"type":108,"coordinates":157},[158,159],34.78057,32.08088,{"lat":159,"lon":158},{"facility":162,"status":101,"city":163,"state":15,"zip":164,"country":145,"countryCode":146,"cosmosGeoPoint":165,"geoPoint":169,"contacts":15},"Chaim Sheba Medical Center","Tel Litwinsky","52621",{"type":108,"coordinates":166},[167,168],34.84588,32.05096,{"lat":168,"lon":167},{"type":171,"investigatorFullName":15,"investigatorTitle":15,"investigatorAffiliation":15,"oldNameTitle":15,"oldOrganization":15},"SPONSOR","100528941",false,"NCT06167317","Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors","A Phase 1 Study to Evaluate the Safety and Tolerability of GS-0201 as Monotherapy and in Combination in Adults With Advanced Solid Tumors","Inclusion Criteria:\n\n* Able to understand and give written informed consent.\n* Assigned female or male at birth, 18 years of age or older, and meet the age of majority\u002Fadulthood per local regulations.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.\n* Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria by investigator assessment.\n* Organ function requirements:\n\n  * Adequate hematologic function\n  * Adequate hepatic function\n  * Creatinine clearance\n  * Coagulation\n* Tissue requirement:\n\n  * Parts A, B, C, and D:\n\n    * Pre-treatment tumor tissue is required.\n  * Parts A and C backfill biopsy cohorts:\n\n    * Individuals must agree to fresh pre- and on-treatment biopsies.\n* Individuals assigned male at birth and individuals assigned female at birth and of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception\n* Willing and able to comply with the requirements and restrictions in this protocol\n* Part A (GS-0201 Monotherapy Dose Escalation) Inclusion Criteria:\n\n  * Histologically\u002Fcytologically confirmed progressive\u002Fadvanced solid tumors with selected molecular lesions.\n  * Individuals must have received, been intolerant to, or been ineligible for all treatment known to confer clinical benefit or have a contraindication to receive the therapy\n* Part B (Dose Expansion) Inclusion Criteria:\n\n  * Disease documented as:\n  * Cohort B1:\n\n    * Histologically or cytologically confirmed progressive\u002Fadvanced selected solid tumor diagnoses harboring defined molecular lesions\n    * Participants may potentially be required to forgo treatment with approved agent(s) to be able to participate in the study\n  * Cohort B2:\n\n    * Histologically or cytologically confirmed progressive\u002Fadvanced solid tumor diagnoses harboring defined molecular lesions not included in Cohort B1\n* Part C (Dose Escalation) Inclusion Criteria:\n\n  * Histologically or cytologically confirmed unresectable locally advanced\u002Fmetastatic selected solid tumors\n* Part D (Dose Expansion) Inclusion Criteria:\n\n  * Disease documented as:\n  * Cohort D1:\n\n    * Histologically or cytologically confirmed unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC)\n  * Cohort D2:\n\n    * Recurrent\u002Fpersistent endometrial cancer\n\nExclusion Criteria:\n\n* Pregnant or lactating females\n* Known hypersensitivity to any of the study drugs, its metabolites, or formulation excipients\n* Requirement for ongoing therapy with or use of any prohibited medications described in the protocol\n* Individuals with myelodysplastic syndrome (MDS)\u002Facute myeloid leukemia (AML) or with findings suggestive of MDS\u002FAML\n* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of GS-0201\n* The therapies listed below within the specified timeframe:\n\n  * Major surgery (excluding minor procedures, eg, placement of vascular access, gastrointestinal\u002Fbiliary stent, biopsy) \\\u003C 4 weeks prior to planned Cycle 1 Day 1\n  * Immunotherapy or biologic therapy \\\u003C 21 days prior to planned Cycle 1 Day 1\n  * Chemotherapy \\\u003C 14 days prior to planned Cycle 1 Day 1, or \\\u003C 42 days for mitomycin or nitrosoureas\n  * Targeted small molecule therapy \\\u003C 14 days prior to planned Cycle 1 Day 1\n  * Receipt of experimental therapy within 21 days or 5 experimental treatment half-lives (whichever is longer) prior to planned Cycle 1 Day 1\n  * Hormonal or other adjunctive therapy for cancers other than the cancer under evaluation in this study that started \\\u003C 14 days prior to planned Cycle 1 Day 1 are not permitted. Hormonal therapy, bisphosphonates, somatostatin analogues, and leuprolide are permitted if started ≥ 14 days prior to planned Cycle 1 Day 1\n  * Radiotherapy within 2 weeks prior to planned Cycle 1 Day 1 and the radiation is not administered to a target lesion\n  * Any prior allogeneic tissue\u002Fsolid organ transplantation, including allogeneic hematopoietic stem cell transplantation. Individuals with a history of autologous hematopoietic stem cell transplantation are also excluded\n* Have not recovered (ie, Grade 1 or lower) from AEs due to a previously administered agent\n* Prior treatment with approved or experimental prohibited agents as detailed in the protocol.\n* Diagnosis of immunodeficiency, either primary or acquired, or requires systemic corticosteroids (\\> 10 mg of prednisone daily, or equivalent). However, replacement doses, topical, ophthalmologic, and inhalational steroids are permitted\n* Have an active second malignancy\n* Have known active central nervous system (CNS) metastases\n* Individuals with carcinomatous meningitis or primary CNS tumors are excluded regardless of clinical stability\n* Meet any of the following criteria for cardiac disease:\n\n  * Myocardial infarction or unstable angina pectoris within 6 months of enrollment\n  * History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication)\n  * QT interval \\> 470 msec\n  * New York Heart Association Class III or greater congestive heart failure or known left ventricular ejection fraction less than 40%\n* Meet any of the following infectious criteria:\n\n  * Have active serious infection requiring antimicrobials\n  * Have active hepatitis B virus (HBV) or hepatitis C virus (HCV), or HIV. In individuals with a history of HBV or HCV, individuals with detectable viral loads will be excluded\n  * Individuals who test positive for hepatitis B surface antigen. Individuals who test positive for hepatitis B core antibody are eligible with a negative HBV DNA by quantitative Polymerase chain reaction (PCR)\n  * Individuals who test positive for HCV antibody. Individuals who test positive for HCV antibody are eligible with a negative HCV RNA by quantitative PCR\n  * Individuals who test positive for HIV antibody\n* History of pneumonitis requiring treatment with corticosteroids, interstitial lung disease, or radiation pneumonitis requiring steroids\n* Symptomatic ascites or pleural effusion\n* Have other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations\n* Any medical condition that, in the investigator's or sponsor's opinion, poses an undue risk to the individuals participation in the study\n* Use of any live vaccines against infectious diseases within 4 weeks (28 days) of initiation of study drug(s) (inactivated, viral vector vaccines, and messenger RNA (mRNA) vaccines are allowed; seasonal vaccines should be up to date prior to planned Cycle 1 Day 1)\n* Parts C (Dose Escalation) and D (Dose Expansion): Combination Cohorts:\n\n  * Individuals with active chronic inflammatory bowel disease (ulcerative colitis, Crohn disease) and individuals with a history of bowel obstruction or gastrointestinal perforation within 6 months prior to planned Cycle 1 Day 1\n  * Individuals who previously received topoisomerase 1 inhibitors or antibody-drug conjugates containing a topoisomerase 1 inhibitor\n  * Known severe intolerance or life-threatening hypersensitivity reactions to humanized monoclonal antibodies or intravenous (IV) immunoglobulin preparations; any history of anaphylaxis; history of human anti-human antibody response\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years",{"count":181,"type":182},278,"ESTIMATED","INTERVENTIONAL",[185],"PHASE1","The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-0201 when given alone or in combination with sacituzumab govitecan (SG) in participants with advanced solid tumors.\n\nThe primary objectives of this study are to:\n\n* To assess the safety and tolerability of GS-0201 as monotherapy and in combination with SG in participants with selected advanced solid tumors\n* To identify the maximum tolerated dose (MTD) and\u002For the recommended Phase 2 dose (RP2D) of GS-0201 as monotherapy and the MTD and\u002For the RP2D and dosing schedule of GS-0201 in combination with SG in participants with selected advanced solid tumors",[188],"Advanced Solid Tumors","2026-05-26",{"date":191,"type":192},"2026-05-28","ACTUAL",{"date":194,"type":192},"2024-01-09",{"date":196,"type":182},"2028-09",{"name":5,"class":6},7]